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Abstract
This article is part of a series written for people responsible for making decisions about health policies and
programmes and for those who support these decision makers.
The term monitoring is commonly used to describe the process of systematically collecting data to
inform policymakers, managers and other stakeholders whether a new policy or programme is
being implemented in accordance with their expectations. Indicators are used for monitoring
purposes to judge, for example, if objectives are being achieved, or if allocated funds are being spent
appropriately. Sometimes the term evaluation is used interchangeably with the term monitoring, but
the former usually suggests a stronger focus on the achievement of results. When the term impact
evaluation is used, this usually implies that there is a specific attempt to try to determine whether
the observed changes in outcomes can be attributed to a particular policy or programme. In this
article, we suggest four questions that can be used to guide the monitoring and evaluation of policy
or programme options. These are: 1. Is monitoring necessary? 2. What should be measured? 3.
Should an impact evaluation be conducted? 4. How should the impact evaluation be done?
About STP
This article is part of a series written for people responsible for
making decisions about health policies and programmes and for
those who support these policymakers. The series is intended to
help such people ensure that their decisions are well-informed
by the best available research evidence. The SUPPORT tools
and the ways in which they can be used are described in more
detail in the Introduction to this series [1]. A glossary for the
entire series is attached to each article (see Additional File 1).
Links to Spanish, Portuguese, French and Chinese translations
of this series can be found on the SUPPORT website http://
www.support-collaboration.org.  Feedback about how to
improve the tools in this series is welcome and should be sent to:
STP@nokc.no.
Scenarios
Scenario 1: You are a senior civil servant with overall responsi-
bility for several healthcare programmes. You wish to ensure
that you have the information necessary to assess how various
programmes are performing and the impact they are having.
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Scenario 2: You work in the Ministry of Health and have been
instructed to prepare a memo on various issues that should be
taken into consideration when the national vaccination pro-
gramme is evaluated.
Scenario 3: You work in a unit supporting the government in
its use of evidence in policymaking. You are preparing a moni-
toring and evaluation plan for the national tuberculosis control
programme.
Background
For policymakers (Scenario 1), this article suggests a
number of questions that their staff might be asked when
planning the monitoring and evaluation of a new policy.
For those who support policymakers (Scenarios 2 and 3),
this article suggests a number of questions to consider
when planning how to monitor the implementation of
policies and programmes, and the evaluation of their
impacts.
Policymakers and other stakeholders will often need to
know whether a new policy or programme has been
implemented in accordance with their expectations. Is the
programme rollout progressing as planned? Are the objec-
tives being achieved, and are the allocated funds being
spent appropriately? Monitoring  is the term commonly
used to describe the process of systematically collecting
data to provide answers to such questions [2]. The term
performance monitoring is often used when the main focus
of an evaluation is comparing "how well a project, pro-
gram, or policy is being implemented against expected
results" [2].
Indicators are frequently used as part of the monitoring
process. An indicator has been defined as a "quantitative
or qualitative factor or variable that provides a simple and
reliable means to measure achievement, to reflect the
changes connected to an intervention, or to help assess
the performance" [2]. An indicator can be a simple count
of events, e.g. the number of vaccinations conducted
within a set period of time, or a construct based on various
data sources, e.g. the proportion of all children being fully
immunised before their first birthday.
The term evaluation  is sometimes used interchangeably
with monitoring, but the former usually suggests a stronger
focus on the achievement of results. These terms are not
used consistently and may mean different things to differ-
ent people. The term impact evaluation is frequently used
when an attempt is made to evaluate whether observed
changes in outcomes (or 'impacts') can be attributed to a
particular policy or programme.
Questions to consider
1. Is monitoring necessary?
2. What should be measured?
3. Should an impact evaluation be conducted?
4. How should the impact evaluation be done?
1. Is monitoring necessary?
The importance of monitoring depends on the perceived
need among relevant stakeholders to know more about
what is happening 'on the ground'.
Determining whether a system for monitoring a policy or
programme should be established may depend on several
factors, including:
• Whether a monitoring system is already in place that
includes the desired indicators, or if a new set of indica-
tors is required
￿ The likely costs of establishing the system required. For
example, could a few new items be added to data collec-
tion procedures already in place, or is it necessary to con-
duct additional large-scale household surveys or to
develop a completely new tool?
￿ Whether the findings are likely to be useful. What
actions should be taken if monitoring reveals that things
are not going as planned?
Monitoring is not worthwhile if data remain unused. Data
are particularly useful if corrective action is undertaken
when a gap is identified between expected and actual
results. Such findings may result in expectations being
reconsidered. This may take the form of assessments, for
example, of whether the initial plans were too ambitious,
or whether a new policy has failed to work as effectively as
expected.
See Table 1 for two illustrative examples of monitoring
systems that have been put in place within health systems
[3,4]
2. What should be measured?
Indicators that focus on various parts of the 'results chain'
(i.e. on inputs, activities, outputs, outcomes or impacts -
see Figure 1) are typically used to monitor the implemen-
tation of a programme or policy option. In some circum-
stances it may be seen as sufficient to monitor inputs (i.e.
the provision of resources such as personnel and equip-
ment). In others it may be important to monitor the activ-
ities of the programme or its outcomes (such as the
number of children fully immunised).Health Research Policy and Systems 2009, 7(Suppl 1):S18 http://www.health-policy-systems.com/content/7/S1/S18
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A number of factors need to be considered when selecting
which indicator(s) to use [5,6]:
￿ Validity: the extent to which the indicator accurately
measures what it purports to measure
￿ Acceptability: the extent to which the indicator is accept-
able to those who are being assessed and those undertak-
ing the assessment
￿ Feasibility: the extent to which valid, reliable and consist-
ent data are available for collection
￿ Reliability: the extent to which there is minimal measure-
ment error, or the extent to which findings are reproduci-
ble should they be collected again by another
organisation
￿ Sensitivity to change: the extent to which the indicator has
the ability to detect changes in the unit of measurement
￿ Predictive validity: the extent to which the indicator has
the ability to accurately predict relevant outcomes
Costs related to data collection and the capacity to analyse
and feed back data to managers and providers may also
limit the choice of indicators. In settings where analytical
resources are scarce, it may be preferable to select a simple
indicator even if it does not have the best predictive valid-
ity, rather than an indicator that requires statistical manip-
ulation.
A trade-off is often apparent between, on one hand, want-
ing to use desired and optimal indicators and on the other
hand, having to use those indicators which are based on
existing data. There are good reasons not to select more
indicators than are absolutely essential. These reasons
Results chain-model (definitions adapted from [2]) Figure 1
Results chain-model (definitions adapted from [2]).
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Table 1: Examples of monitoring systems in the healthcare system
Scaling up provision of antiretroviral therapy (ART) in Malawi [3]
When Malawian health authorities decided to make ART available to a large proportion of the HIV-positive population, a system was put in place to 
monitor the implementation of this new policy. The principles of the system are based on the WHO's approach to the monitoring of national 
tuberculosis programmes. Each patient who starts on ART is given an identity card with a unique identity number, and this is kept at the clinic. The 
information collected from new patients includes their name, address, age, height, the name of their guardian, and the reason for starting ART. 
Patients are asked to attend each month to collect their medication. During their visit, their weight is recorded and they are asked about their 
general health, ambulatory status, work, and any drug side effects. Pill counts are also undertaken and recorded as a way of ensuring drug 
adherence. In addition, the following standardised monthly outcomes are recorded using the following categories:
• Alive: Patient is alive and has collected his/her own 30-day supply of drugs
• Dead: Patient has died while on ART
• Defaulted: Patient has not been seen at all for a period of 3 months
• Stopped: Patient has stopped treatment completely either due to side effects or for other reasons
• Transfer-out: Patient has transferred out permanently to another treatment
Data collected as part of the Malawian monitoring system of the ART rollout may be analysed and used in a variety of ways. Comparisons can be 
made of treatment outcomes for patients who were recruited at different times. If, for example, the rate of switching from first- to second-line 
regimens increases, or rates of mortality do likewise, an increase in drug resistance to the first-line regimen could be the cause. If the rate of deaths 
or defaulters declines, this could indicate that the management of the ART treatment programme is improving. If outcomes are particularly poor in 
certain geographic areas or clinics, action may need to be taken to address this.
Lung cancer surgery in Denmark [4]
Danish authorities issued national clinical practice guidelines for the management of lung cancer prompted by poor outcomes for patients who 
underwent lung cancer surgery. To monitor the implementation of the guidelines, a register of lung cancer patients was established which included 
specific information about those patients undergoing surgery. Indicators selected by the Danish Lung Cancer Registry include the extent (or 'stage') 
of cancer in the body, the surgical procedure used, any complications that occurred, and the survival outcome.
Data from the Danish Lung Cancer Registry are used, among other reasons, to monitor whether national recommendations for lung cancer surgery 
are being followed. Local, regional, and national audits are performed with the purpose of identifying problems or barriers that may impede 
adherence to the national guidelines. Based on these findings, specific strategies are proposed for quality improvement.Health Research Policy and Systems 2009, 7(Suppl 1):S18 http://www.health-policy-systems.com/content/7/S1/S18
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include the need to limit the burden of data collection
within a health system, avoid the collection of data that
are not utilised, and focus on collecting data of higher
quality, even if this means collecting less data overall [7].
Routinely collected information from health systems may
provide valuable data that can be used as a data source for
monitoring purposes. Data can also be collected specifi-
cally for the purpose of monitoring, e.g. through surveys
or interviews. Consideration should be given to the level
of motivation among those expected to collect data. In
many instances, health personnel will need to integrate
data collection into a busy daily schedule. Therefore if the
information being collected has little or no local obvious
value to them, their motivation for undertaking such tasks
may be low. Similarly, if incentives or penalties are asso-
ciated with the findings from the monitoring process (e.g.
where the payment of providers is linked to performance
indicators), the risk of data manipulation or system gam-
ing should be considered.
3. Should an impact evaluation be conducted?
One of the limitations of monitoring activities, as
described above, is the fact that such activities do not nec-
essarily indicate whether a policy or programme has had
an impact on the indicators that have been measured. This
is because indicators used for monitoring will almost
always be influenced by factors other than those related to
particular interventions. This makes it extremely difficult
to determine which factors caused the observed changes.
If monitoring reveals that performance is improving, this
does not necessarily mean that the intervention is the
(only) causal factor. It is conceivable that the indicators
would have improved anyway even in the absence of the
intervention (see Figure 2).
The establishment of a causal relationship between a pro-
gramme or policy and changes in outcomes is at the core
of what impact evaluation is about. What would have
happened to those receiving an intervention if they had
not in fact received it, is the  central impact evaluation
question, according to the World Bank [8].
There may be strong reasons to expect positive results
based on solid documentation from, for example, previ-
ous evaluations. However, very often such evidence is
lacking. Or the evidence available may not be applicable
to the current setting. Thus, there is a real risk that a new
programme may be ineffective or, even worse, cause more
harm than good. This issue is important for policymakers
to clarify when implementing new programmes. It is also
important because of the benefit that such knowledge
could bring to future health policymaking both in the pro-
gramme setting and other jurisdictions.
Conducting impact evaluations can be costly. Whether
such studies represent good value for money can be ascer-
tained by comparing the consequences of undertaking an
evaluation with the consequences of not undertaking an
evaluation. For example, is it likely that a programme
would be stopped or modified if the results proved to be
negative? If the answer is 'no', the value of undertaking an
impact evaluation is clearly limited.
An impact evaluation is generally more likely to represent
value for money when results can be obtained as the inter-
vention is being rolled out. In such circumstances there is
an opportunity to improve or stop the rollout based on
the results of an impact evaluation conducted in the early
stages of implementation. This would provide value for
money in two instances: firstly, when a pilot study is not
possible and, secondly, when it would be possible and
practical to modify or stop the rollout (if needed) based
on the results.
The Mexican government's health insurance scheme, Seg-
uro Popular, is an example of an impact evaluation
embedded in a programme rollout [9-11]. Implemented
in 2001, the scheme was established in order to extend
Comparing change in performance in two areas: one with an  intervention and one without* Figure 2
Comparing change in performance in two areas: one 
with an intervention and one without*. * The Figure 
illustrates that attributing the change from 'Baseline' to 'Fol-
low-up' in response to an intervention is likely to be mislead-
ing. This is because, in this instance, there is also an 
improvement in the 'Control'. Even with regard to the Con-
trol, it is uncertain whether the difference between the 
'Intervention' and 'Control' (i.e. the 'Impact') can, in fact, be 
attributed to the programme or intervention. There may be 
other differences between the 'Intervention' and 'Control' 
settings that might have led to the observed difference in the 
indicator measured
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health insurance coverage to the almost 50 million Mexi-
cans not yet covered by existing programmes. Taking
advantage of the timetable of the progressive rollout, the
government set up an evaluation comparing the outcomes
for those communities receiving the scheme with those
still waiting for it. In addition to evaluating whether the
reform achieved the outcomes intended and did not have
unintended adverse effects, the evaluation also provides
for shared learning.
An impact evaluation may also be useful after a pro-
gramme has been fully implemented, e.g. when there is
uncertainty about continuing a programme. For example,
the conditional cash transfer scheme, Progresa (later
known as Oportunidades), which was introduced in the
mid-1990s provided cash "on the condition that families
fulfil particular elements of co-responsibility, such as
sending children to school rather than work, providing
them with a specially formulated nutritional supplement,
and attending a clinic to receive a specified package of
interventions for health promotion and disease preven-
tion." [12]. For evaluation purposes, 506 communities
were randomly assigned to either enter the programme
immediately or 2 years later [13]. The findings from this
impact evaluation directly informed policy decisions in
Mexico, persuading the government "not only to continue
with the programme, but also to expand it" [12].
4. How should the impact evaluation be done?
Attributing an observed change to a programme or policy
requires a comparison between the individuals or groups
exposed to it, and others who are not. It is also important
that the compared groups are as similar as possible in
order to rule out influences other than the programme
itself. This can effectively be done by randomly allocating
individuals or groups of people (e.g. within geographic
areas) to either receive the programme or not to receive it,
in what is called a randomised trial. Usually such trials are
conducted as pilot projects before a programme is intro-
duced at a national level. But they can also be undertaken
in parallel with full scale implementation, as illustrated by
the Mexican examples given above.
Randomised trials may, however, not always be feasible.
Alternative approaches include the comparison of
changes before and after programme implementation,
with observed changes during the same time period in
areas where the programme was not implemented (e.g. in
neighbouring districts or countries). This is called a con-
trolled before-after evaluation. Alternatively, an interrupted
time-series may be used in which data are collected from
multiple time points before, during, and after programme
implementation.
Simply comparing the value of an indicator before and
after programme implementation is not generally recom-
mended since the risk of misleading findings is high -
observed changes, e.g. HIV-incidence may be caused by
known and unknown factors other than those related to
the programme itself (see Figure 2) [14,15]. An overview
of a number of evaluation designs is provided in Addi-
tional File 2. The weaknesses and strengths of each
method described in Additional file 2 are outlined in
Additional file 3.
Impact evaluations should be planned well ahead of pro-
gramme implementation in conjunction with relevant
stakeholders, including policymakers. After a programme
has been rolled out widely it is usually too late to carry out
baseline measurements or to establish appropriate com-
parison groups. For example, using random assignments
to decide whether communities will be included in a pro-
gramme or not, cannot be done after the programme has
been implemented nationally. Impact evaluations that are
built into a programme from the start are thus more likely
to yield valid findings than those evaluations conducted
as an afterthought. Furthermore, if impact evaluations are
seen as an integrated part of programme implementation,
policymakers and others may be more committed to tak-
ing the findings into account.
The number of individuals or communities required for
an impact evaluation should also be estimated at an early
stage. This will ensure that there is sample size large
enough for meaningful conclusions to be drawn from the
evaluation findings.
In healthcare, as in most other areas, programmes need to
be both effective and  cost-effective. To assess the eco-
nomic aspects of a programme, resource use and costs
must be estimated, preferably based on data collected
from real-life implementation [16]. Decisions on what
economic data to collect should therefore also be made at
an early stage, before the evaluation starts.
Impact evaluations are likely to be most informative if a
process evaluation is included. A process evaluation may
examine whether the programme or policy option was
delivered as intended. It may also investigate the processes
of implementation and change, explore responses to the
programme, and explore reasons for the findings of the
evaluation [17].
See Table 2 for examples of impact evaluations.
Budget, time or data constraints may act as disincentives
to ensuring rigorous implementation of an evaluation.
Such constraints can affect the reliability of impact evalu-
ations in a number of ways:Health Research Policy and Systems 2009, 7(Suppl 1):S18 http://www.health-policy-systems.com/content/7/S1/S18
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￿ By compromising the overall validity of the results, for
example, due to insufficient planning or follow-up, or
through a paucity of baseline data, a reliance on inade-
quate data sources, or the selection of inappropriate com-
parison groups
￿ Through the use of inadequate samples, e.g. due to the
selection of samples that are convenient to sample but
may not be representative, as a result of sample sizes being
too small, or by a lack of sufficient attention to contextual
factors
Such constraints can be addressed by starting the planning
process early or finding ways to reduce the costs of data
collection. It is important to ensure, however, that neither
the possible threats to the validity of the results, nor the
limitations of the sample, are such that the results of the
evaluation will be unable to provide reliable information.
Before conducting an evaluation, an assessment should
therefore be made as to whether an adequate evaluation is
possible. If it is not, an assessment needs to be undertaken
as to whether a programme should be implemented with-
out prior evaluation, in the face of uncertainty about its
potential impacts [18].
Impact evaluations are not worthwhile if the findings are
not used. Results should be used to inform decisions
about whether to continue, change or stop existing pro-
grammes. Clearly, other interests will also need to be
taken into consideration. For instance, decision makers
may elect not to emphasise particular findings from cer-
tain evaluations when such findings conflict with other
interests that are perceived as more important [19]. How-
ever, it is important to avoid the suppression of findings
from impact evaluations, e.g. for political reasons. Failing
to use evaluation findings contradicts one of the main
objectives of conducting such evaluations: to learn from
experience and share the knowledge that has been gener-
ated. Using independent parties to conduct impact evalu-
ations may decrease the risk of having the findings
manipulated or held back from the public.
Conclusion
A number of aspects related to monitoring and evaluation
have been described in this article. At present, many pro-
gramme monitoring and evaluation efforts are commonly
done using methods that do not yield valid assessments of
the implementation of a policy or programme or valid
estimates of effects. Sometimes such evaluations are not
done at all. By taking the issues described in this article
into consideration, policymakers and those who support
them should be able to develop plans that will generate
new and directly useful knowledge.
Resources
Useful documents and further reading
Segone M (ed). Bridging the gap: The role of monitoring
and evaluation in evidence-based policy making.
UNICEF, the World Bank and the International Develop-
ment Evaluation Association. http://www.unicef.org/
ceecis/evidence_based_policy_making.pdf
Table 2: Examples of impact evaluations
Home-based antiretroviral therapy (ART) in Uganda [20-22]
Shortages of clinical staff and difficulties with accessing care due to transportation costs are major obstacles to scaling up the delivery of ART in 
developing countries. One proposed solution is home-based HIV care, where drug delivery, the monitoring of health status, and the support of 
patients is carried out at the home of the patient by non-clinically qualified staff. It is highly uncertain, however, whether this strategy is able to 
provide care of sufficient quality, including timely referrals for medical care, or whether such a system is cost-effective. Therefore, before 
implementing home-based care programmes widely it is important that they are evaluated for their (cost-) effectiveness.
To ensure a fair comparison between home-based and facility-based ART, researchers in Uganda conducted a randomised trial. The study area was 
divided into 44 distinct geographical sub-areas. In some of these, home care was implemented, while in others a conventional facility-based system 
continued to be used. The selection and allocation of areas to receive, and not to receive, the home-based care system, was randomly determined. 
This reduced the likelihood of important differences between the comparisons groups which might otherwise have influenced the study if, for 
example, the districts themselves had decided whether to implement home-based care, or if decisions had been based on an existing preparedness 
to implement home-based care. The random allocation system used was also the fairest way of deciding where to start home-based care since each 
district had an equal chance of being chosen.
The researchers found that the home-based care model using trained layworkers was as effective as nurse- and doctor-led clinic-based care.
Mandatory use of thiazides for hypertension in Norway [23]
As a cost-containment measure, policymakers in Norway decided that thiazides would be prescribed as anti-hypertensive drugs instead of more 
costly alternatives, in those instances where drug expenses were to be reimbursed. The policy was implemented nationally a few months after the 
decision was made. Because critics continued to argue that the new policy was unlikely to lead to the expected results, The Ministry of Health 
sponsored a study to assess the impact of the policy they had implemented.
The mandatory prescription of thiazides for treating hypertension was implemented across Norway with an urgency that made a planned, rigorous 
impact evaluation impossible to conduct. However, by accessing the electronic medical records of 61 clinics at a later stage, researchers extracted 
prescription data ranging from one year before to one year after the new policy was introduced. They analysed the data using an interrupted time-
series. Monthly rates of thiazide prescribing and other outcomes of interest were analysed over time to see if any significant changes could be 
attributed to the implemented policy. Analysis indicated that there was a sharp increase in the use of thiazides (from 10 to 25% over a pre-specified 
three month transition period), following which the use of thiazides levelled off.Health Research Policy and Systems 2009, 7(Suppl 1):S18 http://www.health-policy-systems.com/content/7/S1/S18
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Government. 2007. Washington DC, The World Bank.
http://www.worldbank.org/ieg/ecd/docs/
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and Approaches. 2004. Washington DC. The World Bank.
http://lnweb90.worldbank.org/oed/oeddoclib.nsf/
24cc3bb1f94ae11c85256808006a0046/
a5efbb5d776b67d285256b1e0079c9a3/$FILE/
MandE_tools_methods_approaches.pdf
Framework for Managing Programme Performance Infor-
mation. 2007. National Treasury of South Africa. http://
www.treasury.gov.za/publications/guidelines/FMPI.pdf
Barber S. Health system strengthening interventions: Mak-
ing the case for impact evaluation. 2007. Geneva, Alliance
for Health Policy and Systems Research.
http:www.who.int/alliance-hpsr/resources/Alli
ance%20%20HPSR%20-%20Briefing%20Note%202.pdf
Savedoff WD, Levine R, Birdsall N. When will we ever
learn? Improving lives through impact evaluation. Report
of the Evaluation Gap Working Group. 2006. Washington
DC, Center for Global Development. http://
www.cgdev.org/content/publications/detail/7973/
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mental and quasi-experimental designs for evaluating
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Links to websites
- Independent Evaluation Group (IEG) at the World Bank:
http://www.worldbank.org/ieg - IEG is an independent
unit within the World Bank. IEG assesses what is effective
or not effective with regard to policy options, how a bor-
rower plans to run and maintain a project, and the lasting
contribution of the Bank to a country's overall develop-
ment.
- International Initiative for Impact Evaluation (3ie):
http://www.3ieimpact.org - 3ie seeks to improve the lives
of poor people in low- and middle-income countries by
providing and summarising evidence related to what pol-
icy options work, as well as when and why, and the costs
involved.
- Health Metrics Network: http://www.who.int/health
metrics/en - The Health Metrics Network (HMN) has the
strategic goal of increasing the availability and use of
timely and accurate health information. To achieve this,
HMN identifies strategies for Health Information System
(HIS) development and strengthening, supports countries
in implementing HIS reform, and increases knowledge
about global public goods through research, technical
innovation, and sharing lessons learned.
- NorthStar: 
http://www.rebeqi.org/?pageID=34&ItemID=35 - North-
Star is a tool for planning, conducting and evaluating
quality improvement programmes.
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